Western Health Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2020
NCT04588311
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Western Health | Western Health; ANZIC Research Centre

Active Ingredients

Drugs in Phase 3 Trials (2)

epoetin (Epogen) (1 trial)

sodium chloride (1 trial)

Drugs in Phase 2 Trials (2)

atezolizumab (tecentriq) (1 trial)

obinutuzumab (gazyva) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Injuries (Phase 3)

Brain Injuries, Traumatic (Phase 3)

Multiple Trauma (Phase 3)

Wounds and Injuries (Phase 3)

Wounds, Nonpenetrating (Phase 3)

Wounds, Penetrating (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 4